Goals: To investigate trends in colorectal cancer (CRC) incidence and survival among Hispanics in Texas.
A s the third most commonly diagnosed cancer and the second most common cause of cancer-related death among men and women in the United States, colorectal cancer (CRC) is projected to account for 132,700 new cases and 49,700 deaths in 2015. CRC incidence and mortality rates have declined since 1998, 1 likely due to improved adherence to CRC screening guidelines 2 and more effective cancer-directed therapy. However, recently published data from the Surveillance, Epidemiology, and End Results (SEER) database clearly show a rising incidence of CRC among younger individuals, with annual percentage change (APC) rates highest for distal (sigmoid and rectal) tumors diagnosed in those between the ages of 20 and 39. [3] [4] [5] [6] [7] [8] Hispanics represent the youngest (median age, 27 y) and most rapidly growing ethnic group in the United States. In fact, by 2060, Hispanics are expected to account for >30% of the entire US population. Although the designation "Hispanic" encompasses a population diverse in racial and geographic origin, individuals of Mexican ancestry currently account for the majority of Hispanics in the United States. 9 As compared with non-Hispanic whites (NHWs), Hispanics have poorer access to health care and tend to present with later stage CRC, which likely account for their inferior survival after CRC diagnosis. [10] [11] [12] Given the rapid growth of the young Hispanic population in the United States, the rising incidence of CRC among 20-to 39-year-old Hispanics warrants further investigation.
With >10 million Hispanic residents, Texas is home to 20% of the US Hispanic population. By 2040, Hispanics will account for about half of Texas' total population (18.8 million Hispanics), representing a growth rate of 530% between 1980 and 2040. 13 In light of the rising incidence of young-onset CRC, the rapid growth of the US Hispanic population, and the enrichment of Texas' population for Hispanics of Mexican ancestry, we analyzed data from the Texas Cancer Registry (TCR) to assess trends in CRC incidence and survival among Texans diagnosed with CRC between 1995 and 2010. We hypothesized that an in-depth analysis of the TCR, which includes a Hispanic population larger than that included in published SEER analyses of young-onset CRC, would shed light on a rising health care problem among the most rapidly growing segment of the US population.
MATERIALS AND METHODS

Study Population
Cases of CRC diagnosed in the State of Texas between January 1, 1995 and December 31, 2010 were identified using the TCR, a non-SEER active and passive surveillance system that maintains the most comprehensive cancer database in Texas. 14 The TCR meets the Centers for Disease Control and Prevention's high quality data standards, as well as gold certification from the North American Association of Central Cancer Registries with numerous internal and external quality assurance procedures. 14 We used anatomic site and histologic codes of the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) to define invasive CRCs: adenocarcinoma (814_3), adenocarcinoma in adenomatous polyps (821_3), adenocarcinoma in adenomatous polyposis coli (82203), papillary adenocarcinoma (826_3), mucinous (colloid) adenocarcinoma (848_3), and signet ring adenocarcinoma (84903). Individuals were classified as NHW, African American (AA), Hispanic, or Asian/Pacific Islander based on the standards of the North American Association of Central Cancer Registries, Version 13. 15 We restricted our analysis to persons aged 20 years or older at CRC diagnosis.
Clinical Characteristics
Data pertaining to primary tumor anatomic location, stage at diagnosis, and survival were collected and analyzed. The anatomic location of each tumor was classified according to the ICD-O-3 classification system: right colon (C18.0-C18.4), left colon (C18.5-C18.7, C19.9, C20.9), large intestine NOS (C18.8-C18.9, C26.0), rectosigmoid colon (C18.7, C19.9, C20.9), and colon excluding rectosigmoid colon (C18.0-C18.6, C18.8-C18.9). For the purposes of this study, tumors of the cecum, ascending colon, hepatic flexure, or transverse colon were designated as right-sided tumors, whereas tumors of the splenic flexure, descending colon, sigmoid colon, rectosigmoid junction, and rectum were designated as left-sided tumors. The subsite defined as rectosigmoid colon consisted of the sigmoid colon, rectosigmoid junction and rectum. We classified tumors by these anatomic subsites based on published data suggesting that the distribution of tumors across these subsites has been shifting and that trends vary by ethnicity and race. 5, 6, 16 Stage of disease at diagnosis, as defined by the 1997 and 2000 editions of the SEER Summary Staging Manual, was analyzed by age group, race/ethnicity, and year of diagnosis.
Statistical Analysis
We used annual population estimates for Texas as denominators to calculate incidence rates for CRC. All incidence rates were age-adjusted to the 2000 US standard population by the direct method. We calculated overall incidence rates and incidence rates according to age group (20 to 39, 40 to 49, 50 to 74, 75 + years old), sex, race/ethnicity (NHW, Hispanic, AA), and anatomic subsite (right-sided colon, left-sided colon, rectosigmoid). We selected age categories based on the commonly accepted definition for adolescent and young adults (AYA, 20 to 39 y old), 4 adults who are not routinely offered CRC screening (40 to 49 y old), and adults who are routinely offered CRC screening (50 y and above). APC of CRC incidence rates and their corresponding 95% confidence intervals (95% CI) were used to characterize changes in CRC incidence rates over time. We considered trends statistically significant if the 95% CIs surrounding the APC excluded zero. Observed cause-specific survival at 5 years was calculated and stratified by age, stage at diagnosis, and anatomic subsite. Relative survival could not be calculated because expected survival of Texans by race and ethnicity is currently unknown at this time. We compared 5-year survival percentage between race/ethnicity using w 2 test. We used SEER*Stat version 8.2.1 (http://www.seer.cancer.gov/ seerstat) to conduct all analyses.
RESULTS
Incidence
Between January 1, 1995 and December 31, 2010, 123,083 individuals were diagnosed with CRC in Texas ( Table 1) . Median age at diagnosis was 69 years, with 89% Table 2 while APC rates are listed in Table 3 . Overall, the absolute incidence of CRC was highest among AAs (76.3/100,000), followed by NHWs (60.2/100,000) and Hispanics (50.8/100,000). Between 1995 and 2010, the agestandardized CRC incidence rate for the entire cohort declined from 62.9/100,000 to 48.3/100,000 (APC, À1.8%; 95% CI, À 2.3% to À1.3%; P < 0.01). When we stratified by race/ethnicity, CRC incidence showed statistically significant linear declines in age-standardized incidence among NHWs (APC, À2.0%; 95% CI, À2.5% to À1.5%; P < 0.01) and AAs (APC, À1.2%; 95% CI, À2.0% to À0.5%; P < 0.01), but not among Hispanics (APC, À0.5%; 95% CI, À1.2% to 0.3%; P = 0.18). Incidence patterns differed by age (Table 3 and Fig. 1 ). Although CRC incidence declined over the study period for individuals aged 50 to 74 years (APC, À1.6%; 95% CI, À2.3% to À1.0%; P < 0.01) and 75 + years (APC, À 2.6%; 95% CI, À3.2% to À2.1%; P < 0.01), CRC incidence in individuals aged 20 to 39 years increased by 1.8% (95% CI, 1.2%-2.5%; P < 0.01) annually while remaining relatively stable in individuals aged 40 to 49 years (APC, 0.3%; 95% CI, À0.1% to 0.7%; P = 0.08).
When we stratified by race/ethnicity within age groups, age-standardized incidence rates for CRC among individuals 50 years and above declined by 2.4% (95% CI, À 3.0 to À1.8; P < 0.01) annually in NHWs and 1.3% (95% CI, À2.1% to À0.5%; P < 0.01) annually in AAs. There was no statistically significant decline in CRC incidence among Hispanics 50 and above (APC, À0.6%; 95% CI, À1.4% to 0.2%; P = 0.13); however, closer examination of this age group (Fig. 1C) suggests an initial upward trend in ageadjusted CRC incidence (1995 to 2000), followed by a plateau in 2000 to 2005, then a slightly downward trend in 2005 to 2010. In individuals 20 to 39 years old, age-standardized incidence rates for CRC rose by 2.4% per year in NHWs (95% CI, 1.3%-3.6%; P < 0.01) and 2.6% per year in Hispanics (95% CI, 1.3%-3.9%; P < 0.01) but remained stable among AAs (APC, 0.3%; 95% CI, À 1.5% to 2.1%; P = 0.75) ( Table 3 ). Stratification by sex revealed a rising incidence of CRC among both male and female Hispanics and NHWs ages 20 to 39, but no change among AA men or women ages 20 to 39 (Supplementary Table 2b , Supplemental Digital Content 2, http://links.lww.com/JCG/A245).
Incidence patterns within age and race/ethnicity subgroups varied by anatomic subsite. In older individuals (50 years old and above), the rate of decline in incidence of leftsided tumors was greater than that for right-sided tumors (Table 3) . Although the incidence of both right-sided tumors (APC, 1.5%; 95% CI, 0.2-2.8; P = 0.02) and leftsided tumors (APC, 2.2%; 95% CI, 1.3-3.2; P < 0.01) increased in the 20 to 39 age group, further analysis revealed some important differences among race/ethnicity subgroups. Whereas the incidence of left-sided tumors Rates per 100,000 and age-adjusted to the 2000 US std population.
CRC indicates colorectal cancer; NHW, non-Hispanic white. 
Stage at Presentation and Survival
Individuals between the ages 20 and 39 years were more likely to have distant disease at the time of CRC diagnosis (26%) than those diagnosed between ages 50 and 74 years (19%; P < 0.01) or those diagnosed when 75 or older (14%; P < 0.01) ( Table 4 ). When we examined 5-year cancer-specific survival (CSS) by stage, survival rates were inferior among persons 75 years or older for all stages of disease when compared with individuals in the younger age groups (Table 5) . Five-year CSS of 20 to 39 age group was comparable with that of the 40 to 49 age group for each stage of disease and comparable with that of the 50 to 74 age group for localized and regional disease, but superior for distant disease (19% vs. 12.2%, P < 0.05). Survival rates for AAs were generally inferior to those observed in NHWs and Hispanics for each stage of disease and across all age groups while survival rates for Hispanics and NHWs were equivalent across most age groups and stages of disease (Supplementary Table 3 , Supplemental Digital Content 3, http://links.lww.com/JCG/A246). Although survival rates for distant disease remained lowest among the AA group throughout the study period, the disparity between 5-year CSS for AAs and the other groups diagnosed with localized disease between 1995 and 1998 no longer existed between 2007 and 2010 (P = 0.70).
DISCUSSION
Our analysis of TCR data show that, between 1995 and 2010, the incidence of CRC declined among Texans 50 years old and above and increased among Texans 20 to 39 years old. Among those 50 years and above, CRC incidence declined significantly among NHWs and AAs, but not Hispanics. Although the incidence of both left-sided and right-sided tumors decreased in older patients, the rate of decline was more pronounced for left-sided tumors. Among the youngest (20 to 39 y old) group, CRC incidence increased in NHWs and Hispanics but not AAs. This trend seems to have been driven by a rising incidence of left-sided tumors among NHWs (APC 3.3%) and Hispanics (APC 3.0%). Finally, the demographic findings of our study parallel national data showing a relatively young and growing Hispanic population. Although Hispanics represented only 17% of the total cohort, they represented nearly 30% of those younger than 50 toward the end of the study period.
CRC screening data are not available in the TCR, making it impossible to demonstrate an association between trends in CRC screening and CRC incidence. However, given that CRC screening facilitates both the excision of premalignant polyps and the detection of earlier stage cancer, improved adherence to CRC screening recommendations may account for the declining CRC incidence and downward stage migration among Texans 50 years and above. Furthermore, as endoscopy has been shown to detect distal polyps more easily than proximal ones, 17 more widespread screening could also account for the more rapid decline in the incidence of left-sided CRC when compared with right-sided CRC in individuals of screening age. The disparate rates of decline in CRC incidence among older individuals of different racial/ethnic groups may reflect either divergent rates of polyp incidence due to shifts in culturally dependent CRC risk factors or simply the well-documented lower CRC screening rates among minority populations. 18 The decline in CRC incidence among older AAs may be "catching-up" to that in NHWs due to heightened awareness of the elevated CRC risk in AAs and improved compliance with CRC screening recommendations, whereas the slower rate of decline among older Hispanics may result from slower adoption of CRC screening in this ethnic group. 19, 20 Despite the absence of a statistically significant decline in CRC incidence among Hispanics 50 years and above over the entire study period, the suggestion that CRC incidence may have reached its peak in 2000 and started to decline thereafter (Fig. 1C) may reflect a rising frequency of CRC screening among older Hispanics. 21 In contrast, the rising CRC incidence and stable distribution of stage across the study period among the younger, unscreened population suggest a true increase in CRC incidence rather than an apparent increase resulting from detection bias. In many respects, our findings from the TCR parallel those from SEER. Siegel and colleagues reported that, between 1992 and 2005, the overall incidence of CRC among young adults ages 20 to 49 increased by 1.5% per year in men and 1.5% per year in women. APC rates were highest in the youngest (20 to 29 y) age group (5.2% in men and 5.6% in women), with a rise in left-sided tumors (distal colon and rectum) driving these positive trends. 16 Similar to our study, Siegel's analysis by race/ ethnicity revealed a rising incidence of CRC in young NHWs and Hispanics but not AAs. In contrast to our study, however, Siegel and colleagues reported no change in the incidence of right-sided tumors in NHWs, and they did not report data for right-sided tumors in Hispanics or AAs. In another SEER analysis, Jafri et al 8 reported an overall decline in the incidence of CRC among NHWs, Hispanics, and AAs 50 years and above between 1993 and 2007 and a concomitant rise in individuals below 50 years. Similar to our findings, they reported a rising incidence of CRC in young Hispanics and NHWs; however, they also reported a small but nevertheless positive trend among AAs (relative increase of 15%). In addition to confirming the declining incidence of CRC in older individuals and the rising incidence in younger individuals, the most recent SEER analysis by Bailey et al 3 projects that, by 2030, the incidence rates of colon and rectal cancers will increase by 90.0% and 124.2%, respectively, for 20 to 34 year olds and by 27.7% and 46.0%, respectively, for 35 to 49 year olds.
The etiology underlying the rising incidence of youngonset CRC remains unknown. Although inherited predisposition should always be considered in young patients with CRC, only a minority of young-onset CRC cases can be attributed to a recognized genetic syndrome, and there are no data to suggest that the frequency of any genetic syndrome associated with young-onset CRC is rising. [22] [23] [24] Investigation into potential etiologies underlying the rising incidence of young-onset CRC has therefore shifted toward environmental factors-either a single factor or a combination of factors, with or without concomitant genetic predisposition.
Certain established factors for CRC traditionally seen in older individuals-obesity, diabetes, and metabolic syndrome, to name a few-have become more prevalent in children and adolescents nationwide. However, to date, obesity, metabolic syndrome, and diabetes, have not been shown to be independently associated with young-onset CRC. [25] [26] [27] Over the last few decades, the so-called "Western" diet-characterized by high intake of red meat, fat, and refined sugars and low intake of fiber and whole All  37  38  18  7  26  42  26  7  29  40  25  6  37  38  19  6  39  38  14  9  NHW  1995-1998  34  42  16  8  25  46  22  7  29  40  24  7  34  42  17  7  35  42  13  10  1999-2002  37  40  16  8  28  38  26  8  31  40  24  6  37  40  17  7  38  40  12  9  2003-2006  41  36  17  6  27  42  24  6  31  40  24  5  40  36  18  5  43  35  14  8  2007-2010  41  35  18  6  31  38  25  6  32  38  24  6  41  34  19  5  44  34  15  7  All  38  38  17  7  28  41  24  7  31  39  24  6  38  38  18  6  40  38  13  9  Hispanic  1995-1998  29  43  19  8  21  47  26  6  27  45  22  6  29  44  20  7  33  42  14  12  1999-2002  32  43  18  7  24  43  25  8  26  44  25  5  32  43  18  7  36  40  14  10  2003-2006  36  38  20  6  25  41  29  6  30  40  25  5  37  38  20  5  40  38  14  7  2007-2010  37  37  20  6  25  43  27  5  30  42  25  3  38  37  21  5  42  34  16  8  All  34  40  19  7  24  43  27  6  29  42  24  5  35  40  20  6  38  38  15  9  African American 1995-1998  27  41  22  10  23  46  23  8  26  39  28  6  27  42  24  8  28  39  17  16  1999-2002  29  41  21  9  19  44  31  6  26  42  25  7  30  42  21  8  30  40  18  13  2003-2006  34  35  24  7  21  39  31  9  24  40  32  5  35  34  25  6  36  33  19  11  2007-2010  35  34  25  6  20  45  28  7  28  39  29  4  36  33  26  5  38  32  20  10  All  32  37  23  8  21  44  28  8  26  40  29  5  33  37  24  6  33  36  19  12 grains-has become more common in the United States, Europe, and Asia, and particularly among children and adolescents. 28 Red meat consumption in particular seems to increase the risk for developing CRC, especially left-sided CRC, in a dose-dependent manner, whereas a high-fiber diet seems to lower the risk. Whether red meat increases risk for CRC by exposing the colonic mucosa to potentially carcinogenic preservatives used during processing or by introducing foreign pathogens or hormones that change the colon's microbial and inflammatory milieu is unknown. [29] [30] [31] [32] [33] Hispanics living in the United States consume a larger proportion of red meat than do NHWs and AAs. 28 AAs, when compared with native Africans, consume more animal protein and fat and are colonized with higher levels potentially toxic-producing colonic bacteria. 34, 35 Our data show that, although the absolute incidence of CRC among young Hispanics remained lower than CRC incidence among NHWs and AAs throughout the study period, it rose at a rate similar to that seen in NHWs (APC 2.6% for Hispanics and 2.4% NHWs) and higher than that seen in AAs (APC 0.3%). Worldwide, CRC incidence remains higher among developed countries compared with developing countries, but the incidence of CRC among developing countries (including Latin American countries) is rising. 36 Furthermore, CRC incidence rises with income level, likely due to a higher prevalence of unhealthy diet and sedentary lifestyle among the wealthy. 37 Taken together, these data suggest that "acculturation," in particular the adoption of the Western diet and lifestyle, could explain the rising incidence of CRC among Hispanics in the United States.
In contrast, even within a particular racial/ethnic group, diet and lifestyle vary by socioeconomic status and geographical location and tend to change over time. These confounding factors not only explain some key differences between findings from SEER and regional cancer registries but also make pinpointing a cause of young-onset CRC on epidemiological grounds alone extremely difficult, especially in the context of rapidly shifting demographics. Moving beyond the epidemiology of young-onset CRC into its biological underpinnings will undoubtedly prove critical in future efforts to personalize preventative measures and treatment options.
Although the TCR population is smaller than the SEER population, our study has several strengths. First, as the largest-to-date descriptive analysis of CRC incidence among Hispanics, our study has important implications on the future of CRC epidemiology in an ever-diversifying population. 8 Specifically, our data suggest that the slower rate of decline of CRC in Hispanics 50 years of age and above may reflect slower adoption of CRC screening among the Hispanic population. As the US Hispanic population both grows and ages, reinforcing the importance of CRC screening in Hispanic communities will become increasingly important. At the same time, the rising incidence of CRC among young Hispanics should drive research exploring potentially modifiable risk factors for CRC in this growing population and should raise suspicion among clinicians in any young individual who presents with obstructive symptoms or bleeding. Second, our population was confined to 1 geographic region, which becomes particularly important when implicating environmental exposure as a potential risk factor for disease. Jafri and colleagues showed dramatic regional differences in CRC incidence among Hispanics (from 11.2 per 100,000 in Atlanta to 39.2 per 100,000 in New Mexico), supporting the importance of studying large geographic regions separately.
Finally, in contrast to SEER, the TCR includes CRC incidence and CSS data for all age groups and all 3 major racial/ethnic groups. According to the TCR, 5-year CSS among 20 to 39 year olds was, stage for stage, either comparable or superior to that of older age groups. Because younger cancer patients are, in general, more likely than older patients to receive aggressive antineoplastic therapy due to higher performance status, fewer comorbidities, and more willingness to accept risk, the superior survival among younger CRC patients in the TCR and other population-based studies may simply reflect selection bias rather than inherent tumor biology. 38, 39 Indeed, a pooled analysis of 20,023 patients enrolled in randomized controlled trials for first-line stage IV CRC 40 revealed that, after adjustment for performance status and sex, the youngest patients (those near 18 y old) had inferior overall and progression-free survival when compared with middle-aged patients (those near 57 y old), especially during the first year of treatment. These data suggest more aggressive tumor biology in young patients, who, in the context of these highly controlled trials, would have received the same treatment as their older counterparts. 40 As treatment data are not available in the TCR, we cannot ascertain whether CSS among young patients with stage IV disease in our study fared at least as well as middle-aged and elderly individuals due to more favorable tumor biology or more aggressive antineoplastic therapy. Similarly, we cannot tell whether differences in administration of antineoplastic therapy or inherent tumor biology account for the inferior survival of AAs across all stage of disease. However, the resolution of the initially observed disparity between CSS in AAs with localized CRC compared with CSS in NHWs/Hispanics with localized CRC argues against differences in tumor biology, at least for cases of CRC highly curable with surgery alone.
In summary, our findings from the TCR show that the incidence of CRC is increasing among young adults in Texas and that trends differ by race/ethnicity and tumor location. Of particular concern is the rising incidence of CRC in Texas' rapidly expanding young Hispanic population in the absence of a significant decline among Hispanics of CRC screening age. At the present time, the absolute incidence of young-onset CRC is likely not high enough to warrant universal CRC screening among average-risk individuals younger than 50. However, CRC trends reported from SEER and TCR should alert clinicians to maintain suspicion for CRC in younger patients who present with rectal bleeding, obstructive symptoms, or unexplained anemia and to address any cultural or socioeconomic factors that may compromise CRC screening in populations with documented lower screening rates. Meanwhile, these data should drive clinical and laboratory investigators to better characterize the pathophysiology of young-onset CRC, to account for racial/ethnic disparities in CRC predisposition and survival, and ultimately to propose novel strategies for preventing, detecting, and treating this emerging disease.
